Click on a filter below to refine your search. Remove a filter to broaden your search.
Developing AKI was associated with a significantly increased rate of subsequent dementia; the pattern was consistent across dementia types.
The findings show a greater effect with longer treatment, compared with dipeptidyl peptidase-4 inhibitors.
The use of cholinesterase inhibitors significantly slowed cognitive decline at follow-ups compared with memantine and nonuse.
The estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 versus dulaglutide among older adults.
The ADRD-specific diagnosis intensity varies most for Black, Hispanic and youngest subgroups.
The all-cause dementia risk was greater for those with treated and untreated hypertension compared with healthy controls.
The findings were seen in a large study of older veterans with diabetes.
The median time to dementia was 15 years in the Penn cohort; the estimated probability of dementia at year 10 was 9 to 15% in the PPMI cohort.
Associations were seen for chronic and new-onset anxiety, but not for resolved anxiety, with all-cause dementia risk.
The interventions could reduce the risk factors for dementia, resulting in a cost-savings and a gain in quality-adjusted life years.